News

Newsmogrifydigital2024-07-15T09:24:04+00:00

FEATURED

CONTENT

Mogrify appoints Dr Jonathan Appleby as Chief Scientific Officer

Mogrify Limited (Mogrify^®), a regenerative medicine company developing a novel class of in vivo reprogramming therapies for diseases with high unmet clinical need, announces the appointment of Dr Jonathan Appleby as Chief Scientific Officer.

With decades of industry experience in translating both conventional and advanced therapeutic medicines, Jon will lead advancement of the Company’s therapeutic programs in areas including otology, ophthalmology and diabetes toward and into clinical development.

Latest

NEWS

Mogrify appoints Dr Jonathan Appleby as Chief Scientific Officer

Mark Cavanagh2024-07-26T13:01:54+00:0015th July 2024|

Mogrify extends Series A financing to $46 million USD

Mark Cavanagh2025-08-20T14:48:33+00:002nd October 2023|

Mogrify and Astellas announce collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss

Mark Cavanagh2025-08-20T14:49:23+00:005th July 2022|

Mogrify appoints Tom Graney as Non-Executive Director, Audit Chair and Capital Markets Advisor

Mark Cavanagh2025-08-20T14:49:50+00:002nd November 2021|

Mogrify completes Series A financing totaling $33 million USD

Mark Cavanagh2025-08-20T14:51:12+00:004th May 2021|

Mogrify wins Hewitsons Award for Innovation in Business and Price Bailey Award for Business of the Year at CambridgeshireLive Business Excellence Awards 2020

Mark Cavanagh2025-08-20T14:52:03+00:0026th March 2021|

Load More Posts

Latest

Resources

VIEW ALL RESOURCES

VIEW ALL MEDIA FEATURES

VIEW ALL EVENTS

Follow Us On

Social Media

Tweets by Mogrify